Literature DB >> 12598773

Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men.

Sergio Lo Caputo1, Daria Trabattoni, Francesca Vichi, Stefania Piconi, Lucia Lopalco, Maria Luisa Villa, Francesco Mazzotta, Mario Clerici.   

Abstract

BACKGROUND: Despite multiple, repeated exposures to HIV-1, some individuals never seroconvert. Mucosal and systemic immune correlates of this condition have been analysed in HIV-1-exposed women but no data are available concerning mucosal immunity and HIV-1-specific immune responses in exposed but uninfected men.
DESIGN: We analysed cellular and humoral immune parameters in peripheral lymphocytes, seminal fluid and urethral swabs of 14 recently HIV-1-exposed seonegative (ESN) heterosexual men, seven HIV-seropositive patients and seven healthy controls.
RESULTS: HIV-1-specific IgA were detected in urethral swabs of 11 out of 14 ESN and of six out of seven HIV-seropositive patients; Env- and Gag-specific IFNgamma-producing CD4 and CD8 peripheral lymphocytes were present in ESN and HIV-seropositive patients; seminal lymphocytes, but not peripheral blood lymphocytes, of ESN were enriched in activated populations (CD8CD38RO and CD4CD25). p24-specific cytotoxic T lymphocytes were correlated with the percentage of CD4 in the HIV-seropositive partners. High urethral concentrations of HIV-1-specific IgA were seen in those ESN with the most recent unprotected sexual episode.
CONCLUSIONS: This is the first report of HIV-specific mucosal immunity in ESN men. These data add to the body of knowledge of the immune correlates present in exposed, uninfected individuals and might be important in vaccine design.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598773     DOI: 10.1097/00002030-200303070-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  31 in total

1.  Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Authors:  Luigi Buonaguro; Maria Tagliamonte; Maria Luisa Visciano; Hanne Andersen; Mark Lewis; Ranajit Pal; Maria Lina Tornesello; Ulf Schroeder; Jorma Hinkula; Britta Wahren; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

2.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

3.  Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals.

Authors:  Laura Pattacini; Pamela M Murnane; Erin M Kahle; Michael J Bolton; Jeffrey J Delrow; Jairam R Lingappa; Elly Katabira; Deborah Donnell; M Juliana McElrath; Jared M Baeten; Jennifer M Lund
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-30       Impact factor: 2.205

4.  S100A14 Is Increased in Activated NK Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-NK Crosstalk.

Authors:  Krystal Colón; David W Speicher; Peter Smith; Mack Taylor; David S Metzger; Luis J Montaner; Costin Tomescu
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

Review 5.  Innate and acquired immunity in the human penile urethra.

Authors:  Jeffrey Pudney; Deborah Anderson
Journal:  J Reprod Immunol       Date:  2011-02-24       Impact factor: 4.054

6.  Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs.

Authors:  Eveli Kallas; Kristi Huik; Silver Türk; Merit Pauskar; Ene-Ly Jõgeda; Marina Šunina; Tõnis Karki; Don Des Jarlais; Anneli Uusküla; Radko Avi; Irja Lutsar
Journal:  Med Microbiol Immunol       Date:  2015-12-22       Impact factor: 3.402

7.  Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.

Authors:  L Buonaguro; M L Visciano; M L Tornesello; M Tagliamonte; B Biryahwaho; F M Buonaguro
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Authors:  Qin Lizeng; Charlotta Nilsson; Samer Sourial; Sören Andersson; Olav Larsen; Peter Aaby; Mariethe Ehnlund; Ewa Björling
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys.

Authors:  Norman L Letvin; Srini S Rao; Vi Dang; Adam P Buzby; Birgit Korioth-Schmitz; Dilani Dombagoda; Jenny G Parvani; Ryon H Clarke; Liat Bar; Kevin R Carlson; Pamela A Kozlowski; Vanessa M Hirsch; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

10.  Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection.

Authors:  Catherine A Blish; Ozge C Dogan; Walter Jaoko; R Scott McClelland; Kishorchandra Mandaliya; Katherine Odem-Davis; Barbra A Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.